Tiziana Life Sciences Ltd (FRA:0RP)

Germany flag Germany · Delayed Price · Currency is EUR
1.470
+0.040 (2.80%)
Last updated: Dec 5, 2025, 8:02 AM CET
72.94%
Market Cap 177.73M
Revenue (ttm) n/a
Net Income (ttm) -10.93M
Shares Out n/a
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 60
Open 1.470
Previous Close 1.430
Day's Range 1.470 - 1.470
52-Week Range 0.615 - 2.140
Beta n/a
RSI 47.10
Earnings Date Dec 26, 2025

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for u... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 9
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0RP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.